Neuropsychiatric Disease and Treatment (Feb 2021)
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
Abstract
Jose M Montes,1 Paloma Montes,2 Daniel Hernández-Huerta3 1Psychiatry Service, CIBERSAM, IRYCIS, Hospital Universitario Ramóny Cajal, Madrid, Spain; 2Psychiatry Service, Hospital Universitario de Móstoles Madrid, Spain; 3Psychiatry Service, Hospital Universitario Ramón y Cajal, Madrid, SpainCorrespondence: Jose M MontesPsychiatry Service, Hospital Universitario Ramón y Cajal, Carretera Colmenar Km 9,1, Madrid, 28034, SpainTel +34 91 336 9152Fax +34 91 336 8483Email [email protected]: There are still some unmet needs in the treatment of schizophrenia like the persistence of negative symptoms. Cariprazine is a new-generation antipsychotic with partial agonism of the dopamine receptors, distinct from other antipsychotics by its 10 times greater affinity for D3 receptors. This mechanism of action could be especially favorable on patients with predominant negative symptoms. This report is showing three clinical cases of acute schizophrenia exacerbation that required hospitalization and were successfully treated with cariprazine. All of them had predominant positive symptoms and two of them had substance use. Efficacy of cariprazine was also crucial on negative and cognitive symptoms with excellent tolerability.Keywords: schizophrenia, cariprazine, antipsychotics, negative symptoms, case report
